NEW YORK (GenomeWeb News) – MolecularMD has submitted a Premarket Approval application with the US Food and Drug Administration for a companion diagnostic test to leukemia drug ponatinib.

The Portland, Ore.-based firm said after the close of the market Monday that it had filed for clearance of its BCR-ABL T315I Mutation Test, which detects the T315I mutation in BCR-ABL RNA transcripts in blood using Sanger sequencing technology. It said the test can identify patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia who have the mutation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.